News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.


Media Contact:

Robert Murphy

Director, External Communications,
Otsuka America Pharmaceutical, Inc

Press Release

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Mindset Pharma, Inc. (Mindset) announce that they have entered into a definitive arrangement agreement pursuant to which Otsuka will acquire Mindset for approximately CAD 80 million in an all-cash transaction. This agreement has been executed through Otsuka America, Inc. (OAI), a wholly owned subsidiary of Otsuka. The Otsuka and Mindset boards of directors have approved the transaction. The acquisition is expected to be completed during the fourth quarter of 2023, subject to required procedures.

Press Release

Sumitomo Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced today that the DIAMOND (Developing Innovative Approaches for Mental Disorders) 1 clinical study and the DIAMOND 2 clinical study of ulotaront (generic name; development code: SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, dosed once-daily in acutely psychotic adults living with schizophrenia did not meet their primary endpoint.

US News

Otsuka, a leader in mental health, nephrology and digital innovation, has been recognized for the second consecutive year as a top workplace for disability inclusion by the Disability Equality Index® (DEI).